Israel - English - Ministry of Health

mbi pharma ltd., israel - dexamethasone phosphate ( as sodium phosphate ) - solution for injection / infusion - dexamethasone phosphate ( as sodium phosphate ) 4 mg/ml - dexamethasone - dexamethasone kern pharma is indicated in the treatment of:• endocrine diseases such as nonsuppurative thyroiditis, hypercalcaemia associated with cancer and congenital adrenal hyperplasia.• allergy: severe or disabling allergic conditions resistant to conventional treatments, as in: bronchial asthma, contact or atopical dermatitis, seasonal or perennial allergic rhinitis, hypersensitivity reactions to drugs.• ophtalmic: serious inflammatory and allergic processes, acute and chronic, affecting the eyes, such as: iritis and iridocyclitis, chorioretinitis, choroiditis and diffuse posterior uveitis, optical neuritis, allergic conjunctivitis, allergic marginal corneal ulcers.• inflammatory bowel dis.: systemic treatment in exacerbations of ulcerative colitis and regional enteritis.• dermatological diseases (pemphigus, stevens johnson syndrome, exfoliative dermatitis, severe psoriasis and mycosis fungoides) • respiratory diseases (symptomatic sarcoidosis, berylliosis, loeffler's syndrome)• haematological: acquired )autoimmune( haemolytic anaemia, idiopathic thrombocytopenic purpura in adult, pure red cell aplasia• nephrotic syndrome of the idioplathic type or that due to lupus erythematosus• cerebral edema caused by brain tumor, neurosurgery, brain abscess, bacterial meningitis• collagen diseases: active rheumatoid arthritis with severe progressive course, fast destructive remitting forms and / or extra-articular manifestations, juvenile idiopathic arthritis with severe systemic-onset form (still's disease) or locally with no control, rheumatic fever with carditis, dermatomyositis, polymyositis, sle, temporal arteritis.• infectious diseases: bacterial meningitis – adjunct to antibiotics in suspected pneumococcal meningitis and tb meningitis. severe infectious diseases with toxic states (eg tuberculosis, typhoid, brucellosis;. only with simultaneous anti-infective therapy)• fetal lung maturation• chemotherapy – associated nausea and vomiting• multiple myeloma – part of chemotherapy protocols (eg vad)• prevention and treatment of acute mountain sickness/hace

Australia - English - Department of Health (Therapeutic Goods Administration)

chiesi australia pty ltd - dibasic sodium phosphate, quantity: 4.3 g; monobasic sodium phosphate, quantity: 18.8 g - oral liquid - excipient ingredients: glycerol; saccharin sodium; sodium benzoate; purified water; flavour - for use as part of a bowel cleansing regimen in preparing adult patients for colon surgery or for preparing the colon for x-ray or endoscopic examination.

Malta - English - Medicines Authority

accord healthcare ireland ltd euro house, euro business park, little island cork, t45 k857, ireland - cyclophosphamide - powder for solution for infusion or injection - cyclophosphamide 500 mg - antineoplastic agents

New Zealand - English - Medsafe (Medicines Safety Authority)

link pharmaceuticals ltd - etoposide phosphate 119.3mg equivalent to 100 mg etoposide (includes 5% overage);   - powder for injection - 100 mg - active: etoposide phosphate 119.3mg equivalent to 100 mg etoposide (includes 5% overage)   excipient: dextran 40 nitrogen sodium citrate dihydrate - in combination with other approved chemotherapeutic agents as first-line treatment in patients with small cell lung cancer.

New Zealand - English - Medsafe (Medicines Safety Authority)

link pharmaceuticals ltd - etoposide phosphate 579.4mg equivalent to 500 mg etoposide (includes 2% overage);   - powder for injection - 500 mg - active: etoposide phosphate 579.4mg equivalent to 500 mg etoposide (includes 2% overage)   excipient: dextran 40 nitrogen sodium citrate dihydrate - in combination with other approved chemotherapeutic agents as first-line treatment in patients with small cell lung cancer.

Australia - English - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - potassium phosphate - monobasic; sodium phosphate - dibasic dodecahydrate -

Australia - English - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - potassium phosphate - dibasic; potassium phosphate - monobasic -

Australia - English - Department of Health (Therapeutic Goods Administration)

phebra pty ltd - monobasic sodium phosphate, quantity: 1.936 g - tablet, effervescent - excipient ingredients: potassium bicarbonate; citric acid; sucrose; macrogol 4000; saccharin sodium; sodium bicarbonate; flavour - 1) hypercalcaemia associated with such conditions as hyperparathyroidism, multiple myelomatosis, and metastatic bone disease.,2) hypophosphataemia associated with vitamin d resistant rickets.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - dibasic potassium phosphate, quantity: 183 mg/ml; monobasic potassium phosphate, quantity: 54 mg/ml - injection, concentrated - excipient ingredients: water for injections - indications as at 24 march 2004: treatment of severe hypophosphataemia (serum levels less than 0.3 mmol/l) and other degrees of hypophosphataemia when oral therapy is not possible. the cause of hypophosphataemia should be identified and treated.

Israel - English - Ministry of Health

mbi pharma ltd., israel - dexamethasone as sodium phosphate - solution for injection - dexamethasone as sodium phosphate 4 mg/ml - dexamethasone - dexamethasone kern pharma is indicated in the treatment of:• endocrine diseases such as nonsuppurative thyroiditis, hypercalcaemia associated with cancer and congenital adrenal hyperplasia.• allergy: severe or disabling allergic conditions resistant to conventional treatments, as in: bronchial asthma, contact or atopical dermatitis, seasonal or perennial allergic rhinitis, hypersensitivity reactions to drugs.• ophtalmic: serious inflammatory and allergic processes, acute and chronic, affecting the eyes, such as: iritis and iridocyclitis, chorioretinitis, choroiditis and diffuse posterior uveitis, optical neuritis, allergic conjunctivitis, allergic marginal corneal ulcers.• inflammatory bowel dis.: systemic treatment in exacerbations of ulcerative colitis and regional enteritis.• dermatological diseases (pemphigus, stevens johnson syndrome, exfoliative dermatitis, severe psoriasis and mycosis fungoides) • respiratory diseases (symptomatic sarcoidosis, berylliosis, loeffler's syndrome)• haematologica